MedTrace Logo

Safety and Efficacy of APG-157 in Head and Neck Cancer

NCT05312710 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-01-16

No results posted yet for this study

Summary

The purpose of this clinical research study is to study safety and efficacy of orally administered APG-157 as the neoadjuvant/induction therapy in newly diagnosed, locally advanced patients with Head \& Neck Cancer of oral cavity and/or oropharynx.

The study hypothesis is that neoadjuvant use of APG-157 will reduce the tumor burden prior to any definitive therapy to improve the outcomes over current standard of care.

Conditions

  • Head and Neck Cancer
  • Squamous Cell Carcinoma of Oral Cavity
  • Squamous Cell Carcinoma of the Oropharynx

Interventions

DRUG

APG-157

Treatment

Sponsors & Collaborators

  • Aveta Biomics, Inc.

    lead INDUSTRY

Principal Investigators

  • Marilene B Wang, MD · VA Los Angeles/UCLA

  • Elizabeth Franzmann, MD · University of Miami Sylvester Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-22
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05312710 on ClinicalTrials.gov